Search

Background: there is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: a total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ? 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: the median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that be, NA

Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells in patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether the percentage of ALK-positive cells had a predictive effect in patients with advanced NSCLC who received first-line Alectinib as ALK-TKI. Materials and methods This retrospective study included patients with advanced-stage NSCLC who received alectinib as a first-line ALK-TKI and whose percentage of ALK-positive cells was determined by FISH at 27 different centers. Patients who received any ALK-TKI before alectinib were not included in the study. Patients were separated into two groups according to the median (40%) value of the percentage of ALK-positive cells (high-positive group >= 40% and low-positive group < 40%). The primary endpoint was PFS, and the secondary endpoints were OS, ORR, and PFS of the subgroups based on different threshold values for the percentage of ALK-positive cells. Results 211 patients were enrolled (48.3% female, 51.7% male) to study. 37% (n = 78) of the patients had received chemotherapy previously. After a median of 19.4 months of follow-up, the median PFS was not reached in the high-positive group (n = 113), but it was 10.8 months in the low-positive group (n = 98) (HR 0.39; 95% CI 0.25-0.60, p < 0.001). The median OS in the high-positive group was not reached, whereas it was 22.8 months in the low-positive group (HR 0.37; 95% CI 0.22-0.63, p < 0.001). ORR was significantly higher in the high-positive group (87.2 vs. 68.5%; p = 0.002). According to the cut-off values of < 20%, 20-39%, 40-59%, and >= 60%, the median PFS was 4.5, 17.1, and 26 months, respectively, and could not be reached in the >= 60% group. Conclusion Our study demonstrated that the efficacy of alectinib varies significantly ac, NA

In this paper we generalize a previous construction in order to design perfect autocorrelation sequences over the so-called PSK+ constellation defined by Boztas, and Udaya [2]. We give a number theoretic criterion for the existence of the new sequences with perfect autocorrelation, and discuss some preliminary numerical results on their aperiodic correlations and merit factors., IEEE, IEEE Informat Theory Soc, HUAWEI, VTECH, Qualcomm, Google, Croucher Fdn, IBM, BROADCOM, Mediatek, iSN State Key Lab, INC, ITS, SENG, Hong Kong Polytechn Univ, K C Wong Educ Fdn, NSF, Hong Kong Univ Sci ; Technol, Sch Engn

Seda Kahraman,1 Suayib Yalcin2 1Y&inodot;ld&inodot;r&inodot;m Beyaz&inodot;t University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey; 2Hacettepe University Institute of Cancer, Department of Medical Oncology, Ankara, TurkeyCorrespondence: Suayib YalcinHacettepe University Institute of Cancer, Department of Medical Oncology, S&inodot;hhiye, Ankara, TurkeyTel +90-5053780639Email syalcin@hacettepe.edu.trAbstract: Gastric cancer (GC) is the fifth most common cancer worldwide. Despite recent improvements in treatment quality and options, advanced gastric cancer remains one of the hardest to cure cancers, with a median overall survival (OS) of 10– 12 months and a 5-year OS of approximately 5– 20%. There is an unmet need for further efforts to palliate disease-related symptoms, improve quality of life, increase tumor response rate, and prolong progression free and overall survival while balancing the toxicities of therapy. The most common type of GC is adenocarcinoma, which demonstrates morphological, biological, and clinical heterogeneity. A plethora of genomic alterations and the activation of numerous molecular pathways including human epidermal growth receptor 2 (HER2), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor-2 (FGFR2), mesenchymal epidermal transforming factor receptor (MET), and the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) are responsible for the complex heterogeneity of GC. Efforts to validate the therapeutic effects of inhibiting some of these aberrantly expressed pathways have failed to lead to a clinically meaningful outcome apart from the overexpression/amplification of the HER2 gene, inhibition of which has had a significant impact on clinical practice. The only available biomarkers to guide the effective treatment of patients with advanced GC are HER2 overexpression, MSI/PD-L1 status, and FGFR alterations. Various anti-HER2 agents have been evalua

Bu tezin amacı, Frekans Atlamalı Kod Bölü¸sümlü Çoklu Eri¸sim1 (FH-CDMA), Bluetoothve ultra geni¸s bant gibi popüler sistemlerde kullanılan Optimal Frekans Atlamalı Dizilerin(FHS lerin) olu¸sturulmasıdır. Literatürde optimalli?gi belirleyen sınırlar bulunmaktadır. Buradakioptimallik Lempel-Greenberger ve Peng-Fan anlamındadır. Bu tezde, 1974 den bugüneyayımlanmı¸s optimal FHS üretim metodları incelenmi¸s ve bir tabloda toplanmı¸stır. AyrıcaLempel-Greenberger Sınırı nın keskin bir sınır olup olmadı?gının incelenmesi için 1974 teyayımlamı¸s makalede bulunun optimallik sınırı ve ispatı verilmi¸stir. FHS lerin olu¸sturulmasındakullanılan cebirsel, kombinatorik vs. gibi bir çok metod vardır. Bunların içindencebirsel bir üretim metodu olan ?Iz Fonksiyonu ile üretim yapan 4 makale incelenmi¸s ve bunlarınMAGMA ile gerçekle¸stirimi yapılarak örnekleri incelenmi¸stir. Ayrıca girilen parametreleregöre FHS olu¸sturan yeni bir MAGMA kodu yazılmı¸stır ve yeni optimal dizilerin varlı?gıincelenmi¸stir. Sabit parametreler için optimal FHS ler bulunmu¸stur ancak bunlar henüz birkurala oturtulamamaktadır. Yeni optimal FHS üretim arayı¸sımız devam etmekte olup ilerleyençalı¸smalarımızda, ?Iz Fonksiyonunun yanı sıra di?ger üretim metodları için de benzer bir çalı¸smayürütülebilir.The purpose of this thesis is constructing Optimal Frequency Hopping Sequences (FHSs)which are used in popular systems such as Frequency Hopping-Code Division Multiple Access(FH-CDMA), Bluetooth and Ultra-Wide Band. There are bounds in literature determining optimality.The optimality here is by means of Lempel-Greenberger and Peng-Fan. In this thesis,construction methods of optimal FHSs published since 1974 are analysed and gathered in atable. In addition, so as to examine the sharpness of Lempel-Greenberger Bound, the optimalitybound and its proof given in the paper published in 1974 take place. There are severalmethods for constructing optimal FHSs like algebraic, combinatorial e.t.c.. Four papers givingalgeb

Bu tezin amacı, Frekans Atlamalı Kod Bölü¸sümlü Çoklu Eri¸sim1 (FH-CDMA), Bluetoothve ultra geni¸s bant gibi popüler sistemlerde kullanılan Optimal Frekans Atlamalı Dizilerin(FHS lerin) olu¸sturulmasıdır. Literatürde optimalli?gi belirleyen sınırlar bulunmaktadır. Buradakioptimallik Lempel-Greenberger ve Peng-Fan anlamındadır. Bu tezde, 1974 den bugüneyayımlanmı¸s optimal FHS üretim metodları incelenmi¸s ve bir tabloda toplanmı¸stır. AyrıcaLempel-Greenberger Sınırı nın keskin bir sınır olup olmadı?gının incelenmesi için 1974 teyayımlamı¸s makalede bulunun optimallik sınırı ve ispatı verilmi¸stir. FHS lerin olu¸sturulmasındakullanılan cebirsel, kombinatorik vs. gibi bir çok metod vardır. Bunların içindencebirsel bir üretim metodu olan ?Iz Fonksiyonu ile üretim yapan 4 makale incelenmi¸s ve bunlarınMAGMA ile gerçekle¸stirimi yapılarak örnekleri incelenmi¸stir. Ayrıca girilen parametreleregöre FHS olu¸sturan yeni bir MAGMA kodu yazılmı¸stır ve yeni optimal dizilerin varlı?gıincelenmi¸stir. Sabit parametreler için optimal FHS ler bulunmu¸stur ancak bunlar henüz birkurala oturtulamamaktadır. Yeni optimal FHS üretim arayı¸sımız devam etmekte olup ilerleyençalı¸smalarımızda, ?Iz Fonksiyonunun yanı sıra di?ger üretim metodları için de benzer bir çalı¸smayürütülebilir.The purpose of this thesis is constructing Optimal Frequency Hopping Sequences (FHSs)which are used in popular systems such as Frequency Hopping-Code Division Multiple Access(FH-CDMA), Bluetooth and Ultra-Wide Band. There are bounds in literature determining optimality.The optimality here is by means of Lempel-Greenberger and Peng-Fan. In this thesis,construction methods of optimal FHSs published since 1974 are analysed and gathered in atable. In addition, so as to examine the sharpness of Lempel-Greenberger Bound, the optimalitybound and its proof given in the paper published in 1974 take place. There are severalmethods for constructing optimal FHSs like algebraic, combinatorial e.t.c.. Four papers givingalgeb